CTI Selects Transperfect's Trial Interactive Platform As Its eTMF and Study Start-Up Solution

NEW YORK, March 11, 2015 –TransPerfect, a leading provider of global development and commercialization solutions to the life sciences industry, today announced that CTI Clinical Trial and Consulting Services (CTI) has implemented Trial Interactive as its electronic Trial Master File (eTMF) and Study Start-up solution to streamline global trial management for its development programs.

Trial Interactive is a web-based, 21 CFR Part 11 compliant platform that eliminates the redundancies inherent in paper-based study start-up and TMF management. By providing study stakeholders with real-time access to clinical trial documentation, Trial Interactive cuts out the travel and shipping costs associated with paper review and reconciliation, consolidating clinical trial documentation processes for CTI and its sponsors. With modules for Study Start-up and eTMF, Trial Interactive offers CTI an end-to-end eClinical solution.

“At CTI approximately 80% of our studies meet or exceed enrollment expectations, despite the challenging patient populations we work in, which is due in part to our excellent pre-trial and Start-Up processes,” stated Kevin Schwarz, Chief Operating Officer, CTI. “With its automation and global document management capabilities, Trial Interactive helps us streamline our study management process while meeting regulatory requirements, allowing for remote inspections and even faster Start-Up timelines.”

“We chose the Trial Interactive platform because it is a true paperless application that delivers the innovation and anytime/anywhere accessibility we need in order to serve our nearly one hundred clients in the pharmaceutical and biotechnology industry,” added Louis Minham, Senior Director, Information Technology, CTI. 

Michael Smyth, General Manager of TransPerfect Life Sciences Solutions, stated, “We are excited to have been chosen as a strategic partner of CTI to help them move towards a virtual clinical development program that will meet regulatory requirements. We appreciate that they see the value of the solution, not only for CTI and their sponsors, but for investigative site personnel who will benefit greatly from the added efficiencies it offers.”